Translational Immunotherapy of Brain Tumors

Erscheinungsjahr 2017
ISBN: 978-0-12-802420-1
Verlag: ACADEMIC PRESS

Buch, Englisch, 404 Seiten, Format (B × H): 160 mm x 237 mm, Gewicht: 790 g

Translational Immunotherapy of Brain Tumors gives researchers and practitioners an up-to-date and comprehensive overview of the field. Chapters include adoptive immunotherapy, immunosuppression, CAR therapy of brain tumors, and dendritic cell therapy for brain tumors.

Very few agents have been shown to be efficacious in the treatment of malignant gliomas. Recently, there have been a number of studies demonstrating the potential success of immunotherapy for brain tumors. Immunotherapeutics are becoming the most frequent drugs to be used in cancer therapy. These new breakthroughs, now approved by the FDA, are a part of multiple phase III international trials and ongoing research in malignant glioma, meaning that the information in this cutting-edge book will be of great importance to practitioners and researchers alike.

2018 BMA Medical Book Awards Highly Commended in Oncology

Zielgruppe

<p>Researchers and practitioners in the fields of neuroscience, neurology, neurooncology, and neurosurgery</p>

Autoren/Hrsg.

Sampson, John H.

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Neurologie, Klinische Neurowissenschaft
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Chirurgie Neurochirurgie
• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung

Inhaltsverzeichnis

Section I. Immunological Features of Brain Tumors 1. An Introduction to Immunotherapy in the Treatment of Brain Tumors 2. Immune Constitution of Patients With Brain Tumors 3. The Role of Regulatory T Cells and Indoleamine-2,3-dioxygenase in Brain Tumor Immunosuppression 4. The Role of Myeloid-Derived Suppressor Cells in Immunosuppression in Brain Tumors 5. Tumor-Specific Mutations in Gliomas and Their Implications for Immunotherapy

Section II. Studying Brain Tumor Immunotherapy 6. Preclinical Immunotherapeutic Animal Models for Brain Tumors 7. Imaging Studies in Immunotherapy 8. Immunotherapy Clinical Trials in Neuro-Oncology

Section III. Experimental Brain Tumor Immunotherapies  9. Peptide-Specific Vaccines 10. Immunotoxin Therapy for Brain Tumors 11. Checkpoint Blockade Immunotherapy for Glioblastoma: Progress and Challenges 12. Dendritic Cell Therapy for Brain Tumors 13. Adoptive Immunotherapy Against Brain Tumors 14. Chimeric Antigen Receptor Therapy of Brain Tumors

Über Autor(innen)

Sampson, John H.
John H. Sampson, MD, PhD, MBA

Dr. Sampson is the Robert H. and Gloria Wilkins Distinguished Professor of Neurosurgery and Chair of the Department of Neurosurgery for the Duke University Medical Center. He holds a leadership role in the Duke Cancer Institute's Neuro-Oncology Program and is a recognized leader in the surgical and experimental treatment of brain tumors with a focus on immunotherapy and drug delivery. He has authored more than 220 peer-reviewed publications in this field and serves on the Editorial Boards of the all the major journals in the field.

Dr. Sampson has received special training in the surgical resection of very complex brain tumors. In addition, he has special training in the design and conduct of clinical trials. He did his research training under the internationally renowned scientist, Darell D. Bigner, and Nobel Laureate, Gertrude Elion. He currently focuses his clinical practice on treating patients with both benign and malignant brain tumors and divides his time between his clinical practice and an active research laboratory investigating new modalities of direct brain tumor infusion and immunotherapy.

Dr. Sampson is internationally recognized in the field of neurosurgery and has received a number of national and international awards and grants in recognition of his expertise in neuro-oncology and especially in the area of immunotherapy for brain tumors. He developed a vaccine against a common mutation in brain tumors that was given Breakthrough Therapy Designation by the FDA after it was shown to extend survival in patients with the most malignant form of brain cancer. His work on another vaccine was also recently published in the journal Nature. His work has been highlighted on the CBS Evening News, 60 Minutes, The Wall Street Journal, and The Diane Rehm Show.